The Research and Development Team at Primmune Therapeutics focuses on advancing the discovery and optimization of their orally administered TLR7 agonist. This team collaborates closely to design and conduct preclinical studies, synthesize new compounds, and evaluate their efficacy in enhancing innate immunity for cancer treatment, ultimately aiming to improve patient response rates to immunotherapy.